Medicine and Dentistry
Adjuvant Therapy
15%
Arm
21%
Autologous Stem Cell Transplantation
15%
B Cell
25%
Biopsy
16%
BRCA1
63%
Cancer Cell
17%
Cancer Immunotherapy
12%
Cancer Registry
17%
Cancer Research
18%
Cancer Therapy
16%
Carcinoma in Situ
28%
Cell Function
11%
Cell Therapy
11%
Chemoradiotherapy
22%
Classical Hodgkin Lymphoma
18%
Clinical Trial
14%
Cohort Analysis
33%
Combination Chemotherapy
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
14%
Cytotoxicity
10%
Dendritic Cell
15%
Diagnosis
10%
Diagnostic Accuracy
10%
Diffuse Large B-Cell Lymphoma
18%
Disease
36%
Disease Free Survival
13%
Diseases
39%
DNA Mismatch Repair
18%
Drug Megadose
15%
Endometrial Cancer
37%
Epithelial Cell Adhesion Molecule
14%
Esophageal Cancer
12%
Germ Cell
28%
Granulosa Cell Tumour
18%
Gynecology
12%
Hazard Ratio
16%
Head and Neck Cancer
12%
Heart Right Ventricle Function
11%
Immune Checkpoint Inhibitor
55%
Immune Disorder
18%
Immune Response
19%
Immunity
10%
Immunotherapy
22%
In Vitro
18%
Infection
11%
Ipilimumab
12%
Kidney Graft
28%
Krukenberg Tumor
19%
Long Term Survival
11%
Lung
18%
Magnetic Resonance Imaging
11%
Malignant Neoplasm
45%
Medicine
17%
Melanoma
20%
Microglia
10%
Molecularly Targeted Therapy
18%
Neoadjuvant Chemotherapy
17%
Neoplasm
100%
Nivolumab
10%
Nodular Melanoma
29%
Obstetrics
12%
Oncologist
20%
Organoid
42%
Ovarian Cancer
46%
Overall Survival
46%
Parotid Gland
18%
PARP Inhibitor
10%
Pembrolizumab
13%
Personalized Medicine
11%
Positron Emission Tomography
13%
Primary Central Nervous System Lymphoma
16%
Progenitor Cell
25%
Progression Free Survival
16%
Prospective Study
12%
Protein P53
13%
Proton Therapy
27%
Quality of Life
35%
Radiation Oncology
18%
Radiation Therapy
27%
Radiation Therapy
26%
Recurrence Risk
22%
Recurrent Disease
38%
Salivary Gland
25%
Salpingooophorectomy
37%
Serositis
11%
Serous Carcinoma
44%
Side Effect
39%
Signal Transduction
11%
Squamous Cell Carcinoma
11%
Stem Cell
19%
Stem Cell
14%
Submandibular Gland
16%
Systemic Therapy
20%
T Cell
36%
Targeted Therapy
43%
Tumor Infiltrating Lymphocyte
10%
Uterine Cancer
24%
Vulvar Cancer
18%
Xerostomia
28%
Keyphrases
18F-FDG PET-CT
13%
Advanced Melanoma
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
29%
Autoimmunity
10%
Axicabtagene Ciloleucel
11%
B Cells
18%
Biobank
12%
BRCA1, BRCA2
47%
Breast Cancer Susceptibility Gene 1 (BRCA1)
10%
Cancer Cells
12%
Cancer Patients
28%
Cancer Registry
13%
Cell Therapy
10%
Chemotherapy
10%
Chimeric Antigen Receptor T Cells (CAR-T)
10%
Clinical Application
11%
Clinical Grade
12%
Clinical Trials
12%
Complete Remission
10%
Complete Response
14%
Corticosteroids
10%
Cyclin E1
11%
Diagnostic Accuracy
18%
Disease Pattern
12%
Disease-free Survival
13%
Dose Effect
11%
Dutch
14%
Early Effect
12%
Endometrial Cancer
42%
Esophageal Cancer
37%
Genomic Instability
22%
Germline Pathogenic Variant
31%
Groningen
12%
Gross Tumor Volume
13%
Head-and-neck Cancer
11%
Health-related Quality of Life
21%
High Risk
14%
High-grade Serous Carcinoma
37%
High-grade Serous Ovarian Cancer (HGSOC)
10%
Immune Checkpoint Inhibitor Treatment
10%
Immune Checkpoint Inhibitors
61%
Ipilimumab
13%
Kidney Transplant Recipients
18%
Large B-cell Lymphoma
18%
Long-term Survival
11%
Lung
10%
Lymphoma Patients
11%
Mantle Cell Lymphoma
18%
Melanoma
11%
Metabolic
16%
Mismatch Repair
18%
Mutational Profile
12%
Neoadjuvant
20%
Neoadjuvant Chemoradiotherapy (nCRT)
16%
Netherlands
25%
Nivolumab
11%
Normal Tissue Damage
11%
Obstetrics
12%
Oncological Outcomes
11%
Oncological Treatment
12%
Oncologists
18%
Organoids
18%
Ovarian Cancer
21%
Overall Survival
34%
P53 Abnormal
10%
Partial Response
13%
Patient Cohort
12%
Patient Well-being
14%
Pembrolizumab
13%
Pneumonia
18%
Prognostic Impact
10%
Progression-free Survival
19%
Proton Radiotherapy
17%
Quality of Life
10%
R-CHOP
11%
Radiation Dose
15%
Radiation-induced Xerostomia
18%
Radiotherapy
46%
Recurrence Risk
10%
Replication Speed
10%
Replication Stress
12%
Risk-reducing Salpingo-oophorectomy
37%
Salivary Gland
16%
Salivary Gland Organoids
12%
Salvage Chemotherapy
11%
Sigma Phase
11%
Stem Cells
10%
Stem Progenitor Cells
13%
Survival Outcomes
20%
Systemic Therapy
12%
Targeted Cancer Therapy
18%
Targeted Therapy
37%
Tissue Sampling
11%
Treatment Outcome
10%
Treatment Strategy
12%
Tumor
47%
Tumor Volume
11%
Vulvar Cancer
18%
Vulvar Squamous Cell Carcinoma
13%
Xerostomia
12%
Immunology and Microbiology
Atezolizumab
15%
Autoimmunity
12%
Axicabtagene Ciloleucel
11%
B Cell
68%
Blood Plasma
11%
Brain Cell
9%
Brain Region
9%
Bursitis
9%
Calorie
9%
Cancer Cell
17%
Cancer Immunotherapy
10%
Cancer Tissue
9%
CD20
9%
CD40 Ligand
9%
Cell Phagocytosis
9%
Cells by Function
9%
Cetuximab
10%
Chimeric Antigen Receptor T-Cell
9%
Chromatin Assembly and Disassembly
9%
Clustered Regularly Interspaced Short Palindromic Repeat
9%
Conformation
9%
Cortisol
9%
Cycline
23%
Cyclophosphamide
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Cytokine
11%
Cytokine Release Syndrome
11%
Cytotoxicity
13%
Disease Burden
9%
Disease Free Survival
15%
DNA Damage
12%
DNA Replication
13%
Droplet Digital Polymerase Chain Reaction
9%
Dynamics
21%
Enhancer Region
9%
Enzyme Active Site
9%
Fiber Optics
9%
Fibroblast
9%
Gene Expression
10%
Gene Expression Profiling
10%
Gene Interaction
9%
Genomic Instability
19%
Germ Cell
18%
Granulocyte Macrophage Colony-Stimulating Factor
9%
Gross Tumor Volume
9%
Hematopoietic Cell
10%
Immune Cell Infiltration
10%
Immune Disorder
9%
Immune Response
11%
Immune System Disorders
9%
Immunity
16%
Immunocompetent Cell
13%
Immunoglobulin Heavy Chain
9%
Immunotherapy
34%
Inflammation Response
13%
Inflammatory Disorder
10%
Infrared Radiation
12%
interferon
18%
Interleukin 17
9%
Interleukin 6
12%
Leporidae
9%
Lifespan
9%
Low Drug Dose
30%
Lymphoma Cell
28%
Macrophage
21%
Mechanical Stress
18%
Memory B Cell
9%
Memory T Cell
9%
Metabolism
9%
Mismatch Repair
9%
Mitophagy
9%
Monospecific Antibody
18%
Mouth Mucosa
9%
MYD88
9%
Neck
10%
Oncogene C Myc
10%
Organoid
14%
Overall Survival
38%
P53
9%
Pemphigus vulgaris
9%
Peptidoglycan
9%
Positron Emission Tomography
26%
Radiation Field
9%
Rheumatic Polymyalgia
18%
Salivary Gland
9%
Selenium Blood Level
9%
Signal Transduction
15%
Skinfold
9%
Stem Cell Factor
9%
T Cell
29%
Time Factor
9%
Transcriptomics
9%
Transplant Procedure
9%
Trastuzumab
9%
Tumor Cell
27%
Tumor Immunity
10%
Tumor Necrosis Factor
10%
Tumor Volume
11%
Tumor-Infiltrating Lymphocytes
12%
Viral Disease
9%